Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Vectura Group PLC

+ Add to Watchlist

VEGPF:US

2.2500 USD 0.1500 7.14%

As of 20:10:01 ET on 02/25/2015.

Snapshot for Vectura Group PLC (VEGPF)

Open: 2.2500 Day's Range: 2.2500 - 2.2500 Volume: 435
Previous Close: 2.1000 52wk Range: 1.9700 - 2.9922 1-Yr Rtn: -

Stock Chart for VEGPF

No chart data available.
  • VEGPF:US 2.2500
  • 1D
  • 1M
  • 1Y
2.1000
Interactive VEGPF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VEGPF

Current P/E Ratio (ttm) -
Estimated P/E(03/2015) 98.2769
Relative P/E vs. SPX -
Earnings Per Share (GBP) (ttm) -
Est. EPS (GBP) (03/2015) 0.0150
Est. PEG Ratio -
Market Cap (M USD) 907.15
Shares Outstanding (M) 403.18
30 Day Average Volume 48
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/20/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VEGPF

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for VEGPF

Vectura Group PLC develops inhaled therapies for the treatment of respiratory diseases. The Company's main products are used to treat asthma and chronic obstructive pulmonary disease. Vectura also develops products for lung pathologies and non-respiratory diseases.

Christopher Paul Blackwell "Chris"CEO/Executive DirectorAndrew J OakleyCFO/Exec Dir/Secretary
Gerhard ScheuchChief Scientific OfficerKarl D KeeganChief Corporate Dev Officer
More Company Profile & Key Executives for VEGPF

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil